With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
Study Type
OBSERVATIONAL
Enrollment
40
In the Netherlands, the standard care for patients with moderate-to-severe prurigo nodularis who have failed or are contraindicated to conventional systemic immunosuppressive treatments consists of 300 mg of dupilumab administered subcutaneously every two weeks, following a loading dose of 600 mg administered subcutaneously.
University Medical Center Utrecht
Utrecht, Utrecht, Netherlands
RECRUITINGPeak Pruritus NRS (PP-NRS)
Peak pruritus NRS of the past 24 hours
Time frame: From enrollment to 52 weeks of treatment
Investigator Global Assessment scale of Prurigo Nodularis stage (IGA-PN)
Investigator Global Assessment scale of Prurigo Nodularis stage
Time frame: From enrollment to 52 weeks of treatment
Drug survival
Duration of dupilumab treatment, reasons for discontinuation
Time frame: From enrollment to 52 weeks of treatment
Adverse events
Data on the incidence, severity, relation to dupilumab and clinical consequences of adverse events
Time frame: From enrollment to 52 weeks of treatment
Skin homing T cell subtypes
Time frame: Up to 52 weeks of treatment
Serum levels of relevant proteins
Time frame: Up to 52 weeks of treatment
Systemic epigenetic changes
Time frame: Up to 52 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.